Journals / Türk Biyokimya Dergisi / 2015 / Cilt: 40 - Sayı: 2

[Polikistik over sendromlu kadın hastalarda serum chemerin seviyeleri]

Serum chemerin levels in women with polycystic ovary syndrome

Pages
157–162
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In obese control group chemerin correlated positively with C-reactive protein levels (r=0.738, p=0.037).Conclusion: In this study we could not detect a definitive role of chemerin in the pathophysiology of polycystic ovary syndrome, but its probable role in the development of the syndrome should be investigated with more detailed studies in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study is to investigate the association of serum chemerin levels with metabolic parameters of women with polycystic ovary syndrome.
📊
Key Findings & Data:We compared the metabolic, biochemical and anthropometric parameters of 35 women with polycystic ovary syndrome and 30 body mass index and age matched controls.Results: Chemerin levels of women with polycystic ovary syndrome were similar to that of the control group.
💡
Conclusion & Impact:In obese control group chemerin correlated positively with C-reactive protein levels (r=0.738, p=0.037).Conclusion: In this study we could not detect a definitive role of chemerin in the pathophysiology of polycystic ovary syndrome, but its probable role in the development of the syndrome should be investigated with more detailed studies in the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study is to investigate the association of serum chemerin levels with metabolic parameters of women with polycystic ovary syndrome. Chemerin is an adipocytokine associated with adiposity, insulin resistance and metabolic syndrome, all of which are frequently observed in polycystic ovary syndrome.Methods: This is a prospective case-control study. We compared the metabolic, biochemical and anthropometric parameters of 35 women with polycystic ovary syndrome and 30 body mass index and age matched controls.Results: Chemerin levels of women with polycystic ovary syndrome were similar to that of the control group. Chemerin levels correlated positively with DHEAS (r=0.427, p=0.011) and LH (r=0.407, p=0.015) levels in women with polycystic ovary syndrome. There was a negative correlation between chemerin and lipoprotein-a levels in normal weight women with polycystic ovary syndrome (r=-0.426, p=0.043) and there was a negative correlation between chemerin and triglyceride levels in overweight women with polycystic ovary syndrome (r=-0.669, p=0.024). In obese control group chemerin correlated positively with C-reactive protein levels (r=0.738, p=0.037).Conclusion: In this study we could not detect a definitive role of chemerin in the pathophysiology of polycystic ovary syndrome, but its probable role in the development of the syndrome should be investigated with more detailed studies in the future.

Özet

Amaç: Bu çalışmanın amacı serum chemerin seviyeleri ile polikistik over sendromlu hastaların metabolik parametreleri arasındaki ilişkiyi araştırmaktır. Chemerin adipozite, insulin rezistansı ve metabolik sendrom ile ilişkilidir ve bulgulara polikistik over sendromunda da sık rastlanır.Metod: Bu çalışma prospektif bir vaka-kontrol çalışması olarak planlandı. Kliniğimize başvuran 35 polikistik over sendromlu hastanın metabolik, biyokimyasal ve antropometrik parametrelerini, yaş ve vücut kitle indeksleri eşleştirilmiş 30 kontrol hastasıyla karşılaştırdık.Bulgular: Polikistik over sendromlu hastaların serum chemerin seviyeleri ile kontrol grubunun serum chemerin seviyeleri benzerdi. Polikistik over sendromlu hastalarda serum chemerin seviyeleri, DHEAS (r=0.427, p=0.011) ve LH (r=0.407, p=0.015) seviyeleri ile korele idi. Normal kilolu polikistik over sendromlu kadınlarda serum chemerin ile lipoprotein-a seviyeleri arasında negatif korelasyon tespit edildi (r=-0.426, p=0.043), kilo fazlası olan polikistik over sendromu hastalarında ise chemerin ve trigliserit seviyeleri arasında negatif korelasyon tespit edildi (r=-0.669, p=0.024). Obez kontrol grubunda serum chemerin seviyeleri ile C-reaktif protein seviyeleri arasında pozitif korelasyon tespit edildi (r=0.738, p=0.037). Sonuç: Bu çalışmada chemerinin polikistik over sendromunun patofizyolojisinde açık bir rol oynadığı gösterilemedi, fakat sendromun gelişimine olası katkıları gelecekteki daha ayrıntılı çalışmalarla araştırılmalıdır.

🔖

Cite This Article

GÖRMÜŞ, U., DÜNDER, İ., GÜDÜCÜ, N., KAVAK, Z. N., ALP, E. (2022). [Polikistik over sendromlu kadın hastalarda serum chemerin seviyeleri]. Türk Biyokimya Dergisi, Cilt: 40 - Sayı: 2, 157–162. https://ajindex.com/articles/621144

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89(6):2745-9
  2. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005; 83(5):1343-6
  3. Carmina E. Cardiovascular risk and events in polycystic ovary syndrome. Climacteric 2009; 12 Suppl 1:22-5
  4. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 2008; 23(10):2352-8
  5. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84(9):3110-6
  6. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64(4):355-65
  7. Kutzleb C, Busmann A, Wendland M, Maronde E. Discovery of novel regulatory peptides by reverse pharmacology: spotlight on chemerin and the RF-amide peptides metastin and QRFP. Curr Protein Pept Sci 2005; 6(3):265-78
  8. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148(10):4687-94
  9. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010; 21(11):660-7
  10. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81(1):19-25
  11. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84(10):3666-72
  12. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009; 58(9):1971-7
  13. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152(2):217-21
  14. Lee MK, Chu SH, Lee DC, An KY, Park JH, et al. The association between chemerin and homeostasis assessment of insulin resistance at baseline and after weight reduction via lifestyle modifications in young obese adults. Clin Chim Acta 2013; 421:109-15
  15. Kim SH, Lee SH, Ahn KY, Lee DH,